Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: Results of the Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial

David A. Morrow, Elliott M. Antman, Assaad Sayah, Kristin C. Schuhwerk, Robert P. Giugliano, James A de Lemos, Michael Waller, Sidney A. Cohen, Donald G. Rosenberg, Sally S. Cutler, Carolyn H. McCabe, Ron M. Walls, Eugene Braunwald

Research output: Contribution to journalArticlepeer-review

123 Scopus citations

Abstract

OBJECTIVES: The Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial tested the feasibility of prehospital initiation of the bolus fibrinolytic reteplase (rPA) and determined the time saved by prehospital rPA in the setting of contemporary emergency cardiac care. BACKGROUND: Newer bolus fibrinolytics have undergone only limited evaluation for prehospital administration. In addition, as door-to-drug times have decreased, the relevance of findings from prior trials of prehospital fibrinolysis has become less certain. METHODS: Patients (n = 315) with ST-elevation myocardial infarction (STEMI) were enrolled in 20 emergency medical systems in North America. The time from emergency medical service (EMS) arrival to administration of a fibrinolytic was compared between study patients receiving prehospital rPA and sequential control patients from 6 to 12 months before the study who received a fibrinolytic in the hospital. RESULTS: Acute myocardial infarction was confirmed in 98%. The median time from EMS arrival to initiation of rPA was 31 min (25th to 75th percentile, 24 min to 37 min). The time from EMS arrival to in-hospital fibrinolytic for 630 control patients was 63 min (25th to 75th percentile, 48 min to 89 min), resulting in a time saved of 32 min (p < 0.0001). By 30 min after first medical contact, 49% of study patients had received the first bolus of fibrinolytic compared with only 5% of controls (p < 0.0001). In-hospital mortality was 4.7%. Intracranial hemorrhage occurred in 1.0%. CONCLUSIONS: Prehospital administration of rPA is a feasible approach to accelerating reperfusion in patients with STEMI. Valuable time savings can be achieved in the setting of contemporary transport and door-to-drug times and may translate into an improvement in clinical outcomes.

Original languageEnglish (US)
Pages (from-to)71-77
Number of pages7
JournalJournal of the American College of Cardiology
Volume40
Issue number1
DOIs
StatePublished - Jul 3 2002

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: Results of the Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 trial'. Together they form a unique fingerprint.

Cite this